PolyPid (PYPD) Debt Ratio (2022 - 2026)

PolyPid (PYPD) posted Debt Ratio of 0.04 for Q1 2026, down 5.61% sequentially from 0.04 in Q4 2025, and down 89.76% YoY from 0.41 in Q1 2025.

PolyPid (PYPD) Debt Ratio (2022 - 2026) Analysis & Trends

PolyPid has reported Debt Ratio for 5 years, with the latest figure at 0.04 in Q1 2026.

Quarterly Debt Ratio fell 89.76% year-over-year to 0.04 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 0.04 (down 89.76% YoY) and the FY2025 annual result came in at 0.04, down 84.95% from the prior year.
Debt Ratio slipped to 0.04 in Q1 2026 per PYPD's latest filing, from 0.04 in the prior quarter.
Over five years, Debt Ratio peaked at 0.68 in Q4 2023 and troughed at 0.04 in Q1 2026.
A 5-year average of 0.33 and a median of 0.37 in 2022 frame the typical range for Debt Ratio.
The sharpest annual moves came in 2023 and 2026: Debt Ratio surged 54.73% in 2023, then sank 89.76% in 2026.
Over 5 years, Debt Ratio stood at 0.45 in 2022, then jumped by 51.24% to 0.68 in 2023, then sank by 56.43% to 0.29 in 2024, then sank by 84.95% to 0.04 in 2025, then slipped by 5.61% to 0.04 in 2026.
According to Business Quant data, Debt Ratio over the past three periods registered 0.04, 0.04, and 0.09 for Q1 2026, Q4 2025, and Q3 2025 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Debt Ratio (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn	0.05
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn	-
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn	0.05
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn	0.12
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn	-
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn	0.26
8	Royalty Pharma	26.98 Bn	26.14 Bn	-	0.47
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn	0.03
10	PolyPid	113.30 Mn	106.53 Mn	-	-

Download Data